Yantai Dongcheng Pharmaceutical Group (002675) Fair Value & Analysis
Healthcare · CN · Market cap 10.2B CNY
Analysis
Yantai Dongcheng Pharmaceutical Group (002675) currently trades at ¥12.56, while our model-based Fair Value estimate is ¥5.22 — implying the stock looks roughly 58.4% overvalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. engages in the raw materials, formulations, nuclear medicine, and big health businesses in China and internationally. It operates through API, Formulation, Radio Pharmaceutical, and Others segments. The company offers formulation products, such as powder injections, tablets, capsules, granules, and drop pills for anticoagulation, cardiovascular, anti-tumor, urology, orthopedics, and anti-infection applications. It also provides active pharmaceutical ingredients, including heparin, chondroitin sulfate sodium and calcium, hyaluronic acid, cytochrome C, and collagen, as well as glucosamine hydrochloride, glucosamine sulfate sodium chloride, and glucosamine sulfate potassium chloride; and nadroparin calcium for injection, hydrocortisone sodium succinate for injection, chorionic gonadotrophin for injection, menotropins for injection, ambroxol hydrochloride dispersible tablets, jinjunling capsules, metformin hydrochloride and glibenclamide ta…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.